| |
N
|
AST (IU/L)
|
ALT (IU/L)
|
AST/ALT (AAR)
|
|---|
| |
Mean ± SD
|
Median
|
Min–max
|
AST ≥ 30 IU/L (%)
|
Mean ± SD
|
Median
|
Min–max
|
ALT ≥ 30 IU/L (%)
|
Mean ± SD
|
Median
|
Min–max
|
ALT/ALT > 1.0 (%)
|
|---|
|
Total population who received ultrasonography
|
5999
|
23.4 ± 12.0
|
21
|
8–363
|
15.4%
|
26.2 ± 20.6
|
20
|
2–503
|
26.5%
|
1.06 ± 0.39
|
1.0
|
0.26–7
|
47.8%
|
|
Non-drinkers without fatty liver
|
3781
|
20.9 ± 9.8*
|
19
|
8–363
|
7.6%#
|
20.6 ± 14.6*
|
18
|
2–503
|
13.4%#
|
1.15 ± 0.39*
|
1.1
|
0.26–7
|
60.0%#
|
|
Non-drinkers with fatty liver (NAFLD)
|
1399
|
28.0 ± 13.6*
|
25
|
11–167
|
30.8%#
|
40.7 ± 26.2*
|
33
|
7–291
|
59.4%#
|
0.78 ± 0.26*
|
0.73
|
0.34–2.47
|
14.8%#
|
|
p value
| |
< 0.0001*
| | |
< 0.0001#
|
< 0.0001*
| | |
< 0.0001#
|
< 0.0001*
| | |
< 0.0001#
|
- AST alanine aminotransferase, ALT asparate aminotransferase, AAR AST/ALT ratio, SD standard deviation, NAFLD non-alcoholic fatty liver disease;
- *p value of the Wilcoxon test comparing the AST and ALT levels and AST/ALT ratios in non-drinkers without fatty liver and non-drinkers with fatty liver (NAFLD)
- #p value of the Chi-square test comparing the percentage of AST ≥ 30 IU/L, ALT ≥ 30 IU/L, and ALT/ALT > 1.0 in non-drinkers without fatty liver and non-drinkers with fatty liver (NAFLD)
